Dermaclear Bha Spot Treatment

Description

Manufactured for Dermaquest ®, Inc., located in Hayward, California, this product is produced in the USA. The company can be accessed online at dermaquestinc.com.

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals are advised to apply a small portion of the medication over the affected area using fingertip application. The medication should be gently massaged onto the skin to ensure proper absorption. Reapplication is permitted as needed, depending on the patient's condition and response to treatment.

Contraindications

Use of this product is contraindicated in the following situations:

• Severe skin irritation: Discontinue use and consult a healthcare professional if severe skin irritation occurs.

• Concurrent use of other topical medications: The application of other topical medications simultaneously may lead to increased dryness or irritation of the skin. Only one topical medication should be used unless directed by a healthcare professional.

• Contact with sensitive areas: Avoid contact with the eyes, lips, and mouth to prevent irritation.

Warnings and Precautions

For external use only. This product is not intended for internal use, and ingestion may lead to serious health consequences.

In the event of accidental ingestion, it is imperative to seek emergency medical assistance or contact a Poison Control Centre immediately. Prompt action is crucial to mitigate potential risks associated with swallowing the product.

Healthcare professionals should advise patients to discontinue use and consult a physician if severe skin irritation develops. Additionally, caution is warranted when using this product concurrently with other topical medications, as this may exacerbate skin reactions or reduce efficacy.

No specific laboratory tests or monitoring parameters are recommended for the safe use of this product. However, ongoing assessment of the patient's skin condition is advised to ensure safety and effectiveness during treatment.

Side Effects

Patients should be aware that the product is intended for external use only. In clinical practice, severe skin irritation has been reported; therefore, patients are advised to discontinue use and consult a healthcare professional if such reactions occur. Additionally, caution is warranted when using other topical medications concurrently, as this may exacerbate adverse reactions.

Drug Interactions

Concurrent use of other topical acne medications may enhance the risk of skin dryness or irritation when applied simultaneously or immediately after the application of this product. In such cases, it is advisable to limit the use to one topical medication unless otherwise directed by a healthcare professional.

Additionally, the simultaneous application of other topical medications may lead to similar adverse effects. Therefore, careful consideration should be given to the use of multiple topical agents, and consultation with a healthcare provider is recommended to determine the most appropriate treatment regimen.

Packaging & NDC

Below are the non-prescription pack sizes of Dermaclear Bha Spot Treatment (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Centre is recommended.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is currently no information available regarding the use of DERMACLEAR BHA SPOT TREATMENT during pregnancy. This includes a lack of data on safety concerns, dosage modifications, or any special precautions that should be taken when considering this treatment for pregnant patients. Healthcare professionals are advised to exercise caution and consider the absence of data when prescribing this product to women of childbearing potential. Further studies may be necessary to fully understand the implications of using this treatment during pregnancy.

Lactation

There is no specific information regarding the use of DERMACLEAR BHA SPOT TREATMENT in lactating mothers or lactation considerations. The prescribing information does not address the excretion of the drug in breast milk or its effects on breastfed infants. Healthcare professionals should exercise caution and consider the potential risks and benefits when recommending this treatment to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Centre immediately.

Patients should be instructed to discontinue use and consult a doctor if they experience severe skin irritation or if they are using other topical medications concurrently. It is important to emphasize that while using this product, patients should avoid contact with the eyes, lips, and mouth.

Additionally, healthcare providers should inform patients that using other topical acne medications simultaneously or immediately after applying this product may lead to increased dryness or irritation of the skin. In such cases, patients should use only one medication unless otherwise directed by a healthcare professional.

For patients who are sensitive to sunlight or anticipate increased sun exposure, it is crucial to recommend the use of a sunscreen to protect their skin.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The medication is administered topically, with patients advised to apply a small portion over the affected area using their fingertips and to gently massage it into the skin. Reapplication is permitted as needed. Clinicians should counsel patients to avoid contact with the eyes, lips, and mouth. Additionally, patients who are sensitive to sunlight or anticipate increased sun exposure should use a sunscreen. If severe skin irritation occurs, patients are instructed to discontinue use and consult a doctor. It is also important to note that using other topical medications concurrently may exacerbate dryness or irritation; therefore, only one topical medication should be used at a time unless otherwise directed by a healthcare professional.

Drug Information (PDF)

This file contains official product information for Dermaclear Bha Spot Treatment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)